138 related articles for article (PubMed ID: 19443940)
1. IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide.
Pawlik A; Herczyńska M; Kurzawski M; Safranow K; Dziedziejko V; Juzyszyn Z; Droździk M
Pharmacol Rep; 2009; 61(2):281-7. PubMed ID: 19443940
[TBL] [Abstract][Full Text] [Related]
2. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
3. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Chlubek D; Pawlik A
Pharmacogenomics; 2011 Jan; 12(1):41-7. PubMed ID: 21174621
[TBL] [Abstract][Full Text] [Related]
4. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Cohen S; Schiff M; Weaver A; Fleischmann R; Cannon G; Fox R; Moreland L; Olsen N; Furst D; Caldwell J; Kaine J; Sharp J; Hurley F; Loew-Friedrich I
Arch Intern Med; 1999 Nov; 159(21):2542-50. PubMed ID: 10573044
[TBL] [Abstract][Full Text] [Related]
5. The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis.
Machaj F; Rosik J; Szostak B; Malinowski D; Safranow K; Olędzka G; Wiechec E; Pawlik A
Clin Rheumatol; 2023 Sep; 42(9):2477-2483. PubMed ID: 37289314
[TBL] [Abstract][Full Text] [Related]
6. Association analysis of single nucleotide polymorphisms of proinflammatory cytokine and their receptors genes with rheumatoid arthritis in northwest Chinese Han population.
You CG; Li XJ; Li YM; Wang LP; Li FF; Guo XL; Gao LN
Cytokine; 2013 Jan; 61(1):133-8. PubMed ID: 23148991
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1β, Interleukin1-Ra, Interleukin-10, and tumor necrosis factor-α polymorphisms in Tunisian patients with rheumatoid arthritis.
Lagha A; Zidi S; Stayoussef M; Gazouani E; Kochkar R; Kochbati S; Almawi WY; Yacoubi-Loueslati B
Pathol Biol (Paris); 2015 Sep; 63(4-5):179-84. PubMed ID: 26003199
[TBL] [Abstract][Full Text] [Related]
8. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
Geborek P; Crnkic M; Petersson IF; Saxne T;
Ann Rheum Dis; 2002 Sep; 61(9):793-8. PubMed ID: 12176803
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Ossowski A; Piatek J; Parafiniuk M; Chlubek D; Pawlik A
Eur J Clin Pharmacol; 2012 Apr; 68(4):371-7. PubMed ID: 21997404
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.
Alldred A; Emery P
Expert Opin Pharmacother; 2001 Jan; 2(1):125-37. PubMed ID: 11336574
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids.
de Paz B; Alperi-López M; Ballina-García FJ; Prado C; Mozo L; Gutiérrez C; Suárez A
J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of leflunomide in active rheumatoid arthritis.
Smolen JS; Emery P
Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():48-56. PubMed ID: 11001380
[TBL] [Abstract][Full Text] [Related]
14. [Changes in indices of inflammatory activity in patients with rheumatoid arthritis during early stages of basic therapy with leflunomide].
Balabanova RM; Makolkin VI; Shostak NA; Chichasova NV; Oliunin IuA; Goriachev DV; Loginova TK; Riabkova AA; Petukhova NV; Men'shikova IV
Ter Arkh; 2004; 76(5):28-32. PubMed ID: 15230128
[TBL] [Abstract][Full Text] [Related]
15. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
Kremer JM; Genovese MC; Cannon GW; Caldwell JR; Cush JJ; Furst DE; Luggen ME; Keystone E; Weisman MH; Bensen WM; Kaine JL; Ruderman EM; Coleman P; Curtis DL; Kopp EJ; Kantor SM; Waltuck J; Lindsley HB; Markenson JA; Strand V; Crawford B; Fernando I; Simpson K; Bathon JM
Ann Intern Med; 2002 Nov; 137(9):726-33. PubMed ID: 12416946
[TBL] [Abstract][Full Text] [Related]
16. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
Rodriguez-Rodriguez L; Jover-Jover JA; Fontsere O; Peña-Blanco RC; León L; Fernández-Gutierrez B; Abásolo L
Scand J Rheumatol; 2013; 42(6):433-6. PubMed ID: 23742043
[TBL] [Abstract][Full Text] [Related]
18. The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression.
Alexander D; Friedrich B; Abruzzese T; Gondolph-Zink B; Wülker N; Aicher WK
Cell Physiol Biochem; 2006; 17(1-2):69-78. PubMed ID: 16543723
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial.
Kalden JR; Nüsslein HG; Wollenhaupt J; Burmester GR; Krüger K; Antoni C
Clin Exp Rheumatol; 2008; 26(5):834-40. PubMed ID: 19032816
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
